Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Sun Hwa Kim, Sin Gon Kim, Doo Man Kim, Jeong Taek Woo, Hak Chul Jang, Choon Hee Chung, Kyung Soo Ko, Jeong Hyun Park, Yong Soo Park, Sang Jin Kim, Dong Seop Choi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.

Original languageEnglish
Pages (from-to)e27-e30
JournalDiabetes Research and Clinical Practice
Volume110
Issue number3
DOIs
Publication statusPublished - 2015 Dec 1

    Fingerprint

Keywords

  • Clinical trial
  • Lobeglitazone
  • Randomised trial
  • Thiazolidinediones

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Kim, S. H., Kim, S. G., Kim, D. M., Woo, J. T., Jang, H. C., Chung, C. H., Ko, K. S., Park, J. H., Park, Y. S., Kim, S. J., & Choi, D. S. (2015). Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study. Diabetes Research and Clinical Practice, 110(3), e27-e30. https://doi.org/10.1016/j.diabres.2015.09.009